<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293696</url>
  </required_header>
  <id_info>
    <org_study_id>D6876C00001</org_study_id>
    <nct_id>NCT00293696</nct_id>
  </id_info>
  <brief_title>Casodex/Zoladex Biomarkers in Localised Prostate Cancer</brief_title>
  <official_title>A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tampere</source>
  <brief_summary>
    <textblock>
      To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate
      comparison to chemical castration induced (goserelin) ones
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferation by Ki67,</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>apoptosis marker (TUNEL assay),</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Gleason score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>expression of known androgen-regulated genes,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers of apoptotic pathway,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(novel) genomic transcripts</measure>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide (Casodex), goserelin (Zoladex)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed localised prostate biopsy specimen that contains sufficient
             tumour for evaluation of cell proliferation and apoptosis markers

          2. Patients who are scheduled for radical prostatectomy with curative intents
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teuvo L Tammela, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TUCH</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>May 7, 2007</last_update_submitted>
  <last_update_submitted_qc>May 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2007</last_update_posted>
  <keyword>biomarker study</keyword>
  <keyword>Patients with clinically localised prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

